Carson Smitherman

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

Emily Ko, Nikita Bisht, Bradley Corr, Steven Friedman et autres

us (code pays fourni par la source)

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Lindsay E. Borden, Casey Cosgrove, Christina R. Washington, Samantha Thomas et autres

us (code pays fourni par la source)

Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability

Bradley R. Corr, Samantha Thomas, Paulina Haight, Elizabeth Stock et autres

us (code pays fourni par la source)

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

Sarah S. Lee, Angeles Alvarez Secord, Steven G. Friedman, Erinn M. Hade et autres

us (code pays fourni par la source)

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Paulina Haight, M. Merino Sánchez, Samantha Thomas, Carson Smitherman et autres

us (code pays fourni par la source)

B7-H4 Protein Expression in Endometrial Cancer

Bobby L. May, Nicholas Conway, Tracy Truong, Sarah Linhart et autres

us (code pays fourni par la source)

Racial and Ethnic Differences and Clinical Outcomes of Patients with High Tumor Mutational Burden, High Microsatellite Instability, and Mismatch Repair Deficiency: Real-World Data from the Multi-Institutional Endometrial Cancer Molecularly Targeted Therapy Consortium (Ecmt2)

Sarah S. Lee, Angeles Alvarez Secord, Steven Friedmann, Erinn M. Hade et autres

us, in (code pays fourni par la source)

Geographic disparities in prescribing patterns of molecularly targeted therapy in advanced and recurrent endometrial cancer

Grace Lee, Elizabeth Evans, Alfonsus Adrian Harsono, Bhavana Pothuri et autres

us (code pays fourni par la source)

Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database

Lindsay Borden, Christina Washington, Samantha Thomas, Carson Smitherman et autres

us (code pays fourni par la source)

Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring among patients with advanced or recurrent endometrial cancer

Michael Toboni, Larry Maxwell, Carly Bess Scalise, Tara Berman et autres

us (code pays fourni par la source)

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer

Paulina Haight, M. Merino Sánchez, Samantha Thomas, Carson Smitherman et autres

us (code pays fourni par la source)

EV110/#509 Utility of longitudinal tumor-informed circulating tumor DNA monitoring in patients with high-risk uterine cancer

Michael Toboni, Tara Berman, Carly Bess Scalise, Nicole Hook et autres